Most pharma companies addressing import/export and supply chain risks associated with coronavirus without a dedicated team, finds survey

23 December 2020 (Last Updated December 23rd, 2020 10:14)

Pharmaceutical companies have resorted to different ways to address the challenges posed by the COVID-19 pandemic with respect to supply chain risks including diversification of suppliers and sources.

Pharmaceutical companies have resorted to different ways to address the challenges posed by the COVID-19 pandemic with respect to supply chain risks including diversification of suppliers and sources.

GlobalData has conducted a survey to assess how companies addressed and monitored import/export and supply chain risks associated with coronavirus in the first and third quarters.

Import-exports and supply chain risks Q1 vs Q3

Monitoring of import/export and supply chain risks related to coronavirus: Q1 vs Q3

A majority 45% of the companies in Q1 opined that they do not have a dedicated team to address the risks, but they have committees/working teams that meet up regularly. The percentage declined marginally to 44% in Q3.

A dedicated team was available to address the risks at 38% of the companies in Q1, which declined to 35% in Q3.

Dependence on suppliers to identify the risks increased, from approximately 17% of the companies in Q1 to 21% in Q3.

The analysis is based on responses received from the Pharmaceutical Trade and Supply Chain Survey between 07 July and 30 July 2020.